Device Week Podcast – Episode 20
This article was originally published in The Gray Sheet
On this week's podcast, "The Gray Sheet" team discussed who has filled a newly established FDA position overseeing the device inspections program, the removal of a warning letter from the agency's website tied to an off-label marketing suit, what 23andMe addressed with FDA in order to relaunch a slimmed down direct-to-consumer genetic testing service after a two-year hiatus, bioabsorbable stents and more.
You may also be interested in...
Stephen Hahn’s low visibility period as the newly installed FDA commissioner comes to an abrupt end. Trump offers generous praise amid COVID-19 response – but how quickly might that change to blame?
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.